A discovery-first analysis of 41 candidate markets identifying the six that should follow NZ — with full disposition of every market considered.
The discovery verdict: Six markets emerge from a 41-market screening scored against five criteria — GLP-1 momentum, regulatory ground, DTC channel maturity, and competitive vacancy (the operational gates), plus Made-in-NZ provenance affinity (a positioning-efficiency lever, not a binding gate). Ranked by composite: Australia (14), UAE (14), South Korea (13), Japan (13), Singapore (13), Hong Kong (12). The screening did not surface 27 markets for near-term entry — the US is structurally closed (companion-supplement shelf locked at zero vacancy), and the UK and Canada are deprioritised on competitive crowding (vacancy=1) as large GLP-1 markets that the data does not support as best-in-class entries today.
The most consequential dimension of the screening is which markets the recommended portfolio leans into and why. Within the six, Australia, UAE, Japan, Singapore, and Hong Kong already register NZ-provenance as a recognised premium signal — pre-existing consumer trust that compresses customer acquisition cost and brand-building time at launch. South Korea joins on the strength of a pure-private-pay GLP-1 cohort and K-Wellness positioning, with NZ-affinity contributing at 2/3 rather than anchoring. Markets where NZ-affinity is weaker — Poland (PLN 3.4 billion in 2025 GLP-1 spend), Brazil (60% of the LATAM market), India's metro-elite cohort, and most of continental EU — remain viable entry candidates on the product's underlying merits: formulation quality, clinical positioning, and ingredient story. They require a different positioning architecture than the NZ-provenance lever that anchors the near-term six, and they are sequenced later in the portfolio, not excluded from it.
The recommended portfolio is geographically deliberate. Australia is the foundation move — the TTMRA gives Nouri a near-frictionless TGA pathway and AU is NZ's second-largest export destination. UAE is the Gulf beachhead — the NZ-UAE Comprehensive Economic Partnership Agreement entered force August 28, 2025, with 98.5% of NZ goods duty-free at entry and a target of tripling bilateral trade to USD 5B by 2032.[1] South Korea is the cleanest near-term Asian launch — Wegovy launched October 2024 with ZERO national reimbursement, so every one of the ~400,000+ patients is already paying ₩200–800K/month privately.[2] Japan is the highest-trust NZ-provenance market in Asia, with a documented and unaddressed off-label cosmetic-GLP-1 demographic served by 67+ clinics nationwide.[3] Singapore is the SEA bridgehead — the HSA framework is among the world's most predictable supplement regulators, English-labeling sufficient, and Singapore operationally seeds 650 million people across Malaysia/Indonesia/Thailand/Vietnam/Philippines. Hong Kong is the premium standalone-plus-China-bridge — small absolute market, highest spend-per-user in the region, and the cleanest legal corridor into mainland China via Tmall Global cross-border ecommerce.[4]
The recommended entry sequence is three waves over 18–24 months: Wave 1 (Australia, 0–6 months post-NZ launch) under TTMRA; Wave 2 (South Korea + UAE, 6–12 months) as the near-term high-momentum cohorts; Wave 3 (Singapore + Hong Kong + Japan, 12–18 months) as the platform plays for regional expansion. Each wave's gating events, pre-launch investments, and risk profile are detailed in Section 10.
The methodology, full scorecard for all 41 markets, and per-market rejection rationale are documented in the supporting research files for audit.
The defining methodological commitment of this analysis was to let the markets emerge from the data, not from a prescribed list. The strategic question — which markets should follow NZ — required a reproducible answer, one where any subsequent challenge of the form "why not market X?" can be met with a specific failing criterion rather than a judgement call.
The universe was built bottom-up from primary GLP-1 adoption signals. A country entered the universe if BOTH of the following were documented in public sources: (a) a semaglutide (Ozempic/Wegovy/Rybelsus) or tirzepatide (Mounjaro/Zepbound) product is officially regulator-approved AND commercially launched (not gray-market only) in 2024–2026, AND (b) at least one public data point exists on prescription volume, sales revenue, active patient count, or formulary status. The resulting universe was 41 markets across 5 regions: North America (3), Europe (20), Middle East (5), Asia-Pacific (11), Latin America (2). Source basis included IQVIA Institute's "Global Use of Medicines 2024,"[5] Novo Nordisk and Eli Lilly investor disclosures, EMA medicine registry, and country-level regulator websites.
| Criterion | What it measures | Score 3 (strong) requires |
|---|---|---|
| GLP-1 momentum | Active user base + growth + regulatory + reimbursement | >1M active users OR documented out-of-pocket spend >€500M annually OR documented >100% YoY growth on substantial base |
| Made-in-NZ affinity | NZ-brand trust + premium-provenance import behaviour | Top-10 NZ export destination AND strong premium NZ brand presence (Comvita / a2 Milk / Manuka Health / Fonterra) AND FernMark trademark filing |
| Regulatory ground | Time-to-market + claim language permissiveness + GMP route | No pre-market registration required OR <60-day notification with reliance pathway (Access Consortium etc.) |
| DTC channel maturity | Subscription supplement viability + payment + logistics | Multiple proven DTC supplement subscription brands operate at scale; cross-border ecommerce viable |
| Competitive vacancy | Absence of locked-in GLP-1 companion incumbent | No dedicated GLP-1 companion brand AND existing weight-management incumbents not pivoted |
The five criteria are not co-equal in how they bind. GLP-1 momentum, regulatory ground, and DTC channel maturity are operational gates: a market without an active GLP-1 cohort cannot support a companion supplement; a market without a viable regulatory pathway cannot be entered legally; a market without DTC channel maturity cannot be sold into at scale. Competitive vacancy is a structural-feasibility check — a 0 indicates the companion shelf is already locked at scale (the US case), a 1 indicates a crowded but possibly-enterable category (UK, Canada). Made-in-NZ affinity is a positioning-efficiency lever: where it scores high, NZ-provenance compresses customer acquisition cost and brand-building time at launch; where it scores low, the market is still enterable, but on a different positioning architecture (clinical authority, pharmacy-channel B2B2C, ingredient-origin storytelling, or premium-imported-wellness positioning) rather than the Aotearoa-provenance lever.
The threshold follows the criteria tiering. A market must score ≥2 on all three operational gates (GLP-1 momentum, regulatory ground, DTC channel maturity); below that, the operational substrate to launch and sell isn't present. Competitive vacancy=0 is a separate, structural fail — the US, despite the largest GLP-1 market in the world, scored 10/15 because Vitamin Shoppe, Nature Made, Thorne, Lemme, Herbalife, and Hims/Eucalyptus have entrenched the companion shelf at scale; a new entrant cannot win the customer-acquisition battle against incumbents at that density. NZ-affinity=0, by contrast, is not disqualifying: it means the market needs non-NZ-anchored positioning to be entered, not that the market is closed. Composite-sum totals are informational; the criteria-tier reading is what determines near-term portfolio membership.
The full scorecard sorted by composite:
| Rank | Country | GLP-1 | NZ | Reg | DTC | Vacancy | Composite | Status |
|---|---|---|---|---|---|---|---|---|
| 1 | Australia | 3 | 3 | 3 | 3 | 2 | 14 | CLEAR |
| 2 | United Arab Emirates | 3 | 3 | 2 | 3 | 3 | 14 | CLEAR |
| 3 | South Korea | 3 | 2 | 2 | 3 | 3 | 13 | CLEAR |
| 4 | Japan | 3 | 3 | 2 | 2 | 3 | 13 | CLEAR |
| 5 | Singapore | 2 | 2 | 3 | 3 | 3 | 13 | CLEAR |
| 6 | United Kingdom | 3 | 3 | 3 | 3 | 1 | 13 | Marginal — vacancy=1 |
| 7 | Hong Kong SAR | 2 | 3 | 3 | 2 | 2 | 12 | CLEAR |
| 8 | China (mainland, CBEC route) | 3 | 3 | 1 | 3 | 2 | 12 | Marginal — regulatory=1 |
| 9 | Canada | 3 | 2 | 3 | 3 | 1 | 12 | Marginal — vacancy=1 |
| 10 | Ireland | 2 | 2 | 3 | 2 | 2 | 11 | CLEAR (lower priority) |
| 11 | Taiwan | 2 | 3 | 2 | 2 | 2 | 11 | CLEAR (lower priority) |
| 12 | Saudi Arabia | 3 | 3 | 1 | 2 | 2 | 11 | Marginal — regulatory=1 |
| 13 | Malaysia | 2 | 2 | 2 | 2 | 2 | 10 | CLEAR (lower priority) |
| 14 | United States | 3 | 2 | 2 | 3 | 0 | 10 | Rejected — vacancy=0 |
| 27 additional countries scored composite 6–11 and did not surface for near-term entry on the criteria-tier reading. See Section 10 for the full disposition. | ||||||||
The deep-dive set was selected from the qualifying group plus consideration of strategic role: Australia + UAE + South Korea + Japan + Singapore + Hong Kong (6 markets). Ireland, Taiwan, and Malaysia cleared the gate but were ranked as second-priority — viable expansion candidates but with smaller absolute markets and less differentiated strategic role than the six selected. They remain on the watch list.
The six deep-dive markets fall naturally into three strategic groups, each with a different role in Nouri's expansion plan:
| Wave | Market | Composite | Strategic role | Recommended timing |
|---|---|---|---|---|
| 1 — Foundation | Australia | 14 | Trans-Tasman scale; second home market | 0–6 months post-NZ |
| 2 — Near-term high-momentum | United Arab Emirates | 14 | Gulf beachhead; CEPA bilateral tailwind | 6–12 months post-NZ |
| South Korea | 13 | Largest pure-OOP GLP-1 cohort in Asia | 6–12 months post-NZ | |
| 3 — Platform plays | Singapore | 13 | SEA bridgehead; 650M-person hub | 12–18 months post-NZ |
| Hong Kong SAR | 12 | Premium standalone + China-mainland bridge | 12–18 months post-NZ | |
| Japan | 13 | Highest-trust NZ-provenance market in Asia | 12–18 months post-NZ |
Three patterns underwrite the portfolio. First, every market has an active or imminent NZ free-trade agreement: TTMRA (Australia, in force decades), NZ-UAE CEPA (in force August 2025), KNZFTA (South Korea, in force 2015), AANZFTA + bilateral CEP (Singapore + ASEAN), NZ-HK CEP (in force 2011), and Japan via CPTPP. The duty-free trade lanes are real, not theoretical. Second, every market has a credible premium-NZ-brand precedent — a2 Milk, Comvita, Manuka Health, Zespri, and Fonterra have already done the consumer-education work, and FernMark trademark protection extends to 43 jurisdictions including all six. Third, every market is in the GLP-1 companion category's empty-shelf window: no dedicated GLP-1 companion brand has captured the position in any of the six.
The exception worth naming: Australia carries vacancy=2 (not 3) because Eimele, JSHealth, and Naked Harvest are AU-domestic premium DTC supplement brands that could plausibly pivot to GLP-1 positioning within 12–18 months, and Hims & Hers acquired Eucalyptus (Juniper's parent) for USD 1.15 billion in February 2026, giving the combined entity AU GLP-1 telehealth scale that could be bundled with companion supplements at any time. Australia is the strongest near-term opportunity AND the fastest-closing window.
Headline: Australia is the structurally lowest-friction expansion market on the planet for a NZ-manufactured supplement brand. TTMRA collapses regulatory friction to near zero, AU represents ~38% of NZ processed-food exports, and the GLP-1 market is at ~497,000 units dispensed monthly (April 2025) — with 180,000–240,000 Australians accessing GLP-1 drugs via the private market at AUD $345–$550/month.[6] The watch-out is the velocity, not the vacancy: JSHealth is signalling intent, Hims & Hers now owns the dominant AU GLP-1 telehealth stack (Eucalyptus / Juniper / Pilot), and Naturecan already has an active AU GLP-1 bundle. The category is open but closing in months, not years.
Australia's GLP-1 user base sits at ~490,000–500,000 active patients, with TAM scaling from AUD $132–$288M in 2025 to AUD $700M–$1.2B by 2030 contingent on PBS Wegovy listing. Regulatory ground is the cleanest globally for a NZ-origin supplement — TGA ARTG via TTMRA mutual recognition, with AANA marketing enforcement active (70+ infringement notices issued against 19 entities in 8 months of 2024). Blended DTC CAC benchmarks at AUD ~$150 for Health & Wellness category at Tier-1 Meta/Google CPMs. Incumbent supplement giants (Blackmores, Swisse, JSHealth) have not yet launched GLP-1-positioned products. The strategic case for Australia-first rests on what the TTMRA actually unlocks.
The Trans-Tasman Mutual Recognition Arrangement — in force since 1998 — is the single most consequential bilateral arrangement for Nouri's AU entry. Under TTMRA, a product lawfully sold in New Zealand can be sold in Australia (and vice versa) without re-registration, with limited exceptions. For dietary supplements, this means a NZ-Medsafe-compliant product enters the AU market with a substantially compressed TGA process. The TGA ARTG (AUST L) listing pathway, which would normally take 4–8 weeks for a straightforward formulation, can be further accelerated where TTMRA mutual recognition is invoked. Nouri's vitamin/mineral system and clear whey isolate should both qualify for the AUST L listed-medicines pathway, which uses 778 permissible indications via self-certification. Critical operational point: the AANA Food & Beverages Code still applies to all marketing, and 70+ infringement notices totalling AU$1 million were issued against 19 entities in just 8 months of 2024 — the regulatory lift is in marketing claim discipline, not product registration.[7]
Australia is New Zealand's #2 export destination by value, with deep and durable premium-NZ-brand penetration in AU supplement aisles. a2 Milk sells premium milk and infant formula in every AU supermarket. Comvita Manuka honey holds shelf position in Woolworths, Coles, and Chemist Warehouse. Manuka Health and Living Nature have direct AU retail distribution. The "Made in NZ" premium has been priced in for decades: AU consumers routinely pay 15–30% premiums for NZ-origin natural-health products versus AU-domestic equivalents, on the same provenance trust signal that anchors Nouri's positioning. FernMark licensing applies in Australia, and the cross-Tasman consumer affinity is the strongest of any non-NZ market analysed.
Four specific competitive realities define the vacancy-2 score. Naturecan (UK-origin, internationally distributed) operates an active GLP-1 Bundle on naturecan.com.au — berberine, omega-3, digestive gummies, and Reducose. It is the only branded GLP-1 companion product currently in the AU market, but with limited brand equity and no AU-native DTC infrastructure. JSHealth Vitamins (Jessica Sepel, AUD $600M+ valuation, 1,800+ AU retail stockists) is the most credible near-term incumbent threat: Sepel's 2026 wellness predictions piece in Women's Health AU explicitly cites "22% of GLP-1 users develop nutritional deficiencies within 12 months" — positioning language, not coincidence.[8] No dedicated JSHealth GLP-1 SKU has launched as of May 2026, but the intent signal is unmistakable. Hims & Hers closed the USD $1.15B Eucalyptus acquisition in February 2026, gaining Juniper (200,000+ AU women patients), Pilot, and the dominant AU GLP-1 telehealth stack.[N11] Hims already bundles supplements with GLP-1 subscriptions in the US; AU integration is the natural next step. Eimele, Blackmores, Swisse, Naked Harvest have NOT launched GLP-1-positioned products as of May 2026 — the broader incumbent field is still uncommitted, but the window is measured in months, not years.
Wave 1 — enter AU 6–9 months post-NZ launch, tightened from the initial 6–12 month plan. Three factors compress the timing: (1) Hims & Hers integration risk — if AU GLP-1 supplement bundling launches via Juniper/Pilot before Nouri arrives, it eliminates the telehealth partnership channel AND the first-mover positioning; (2) JSHealth pre-launch signalling makes a 2026/early-2027 dedicated SKU launch likely; (3) PBAC's November 2025 Wegovy recommendation is narrower than initially read — it covers only adults with established cardiovascular disease (prior heart attack, stroke, or symptomatic PAD) plus obesity, not general obesity.[9] PBS subsidy will expand access for CVD patients but Nouri's target customer (proactive premium DTC buyer) is predominantly the private-pay cohort, which is already fully served. PBS listing is a tailwind, not a prerequisite. The Ozempic shortage was lifted July 18, 2025; supply is no longer constrained. Pre-launch investments: TGA ARTG application via TTMRA + AUST L self-certification (weeks); AU-resident sponsor entity; FernMark licensing; Chemist Warehouse buyer engagement (50–100 store pilot achievable in 6–9 months); telehealth partnership outreach to independent AU GLP-1 prescribers (before Hims forecloses that channel via exclusive relationships).
Headline: The UAE is the highest-momentum, highest-affluence GLP-1 market outside the Anglosphere and East Asia, with vacancy=3 (no incumbent GLP-1 companion brand exists), and the bilateral plumbing into NZ is unprecedented — the NZ-UAE Comprehensive Economic Partnership Agreement entered force August 28, 2025 with 98.5% of NZ goods duty-free and a target of tripling bilateral trade to USD 5B by 2032. The watch-out is the regulatory pathway in transition: the Emirates Drug Establishment (EDE) replaced MOHAP for dietary supplement registration effective December 29, 2025, with a one-year grace period and active portal/document evolution through 2026.
The 2025 Dubai Academic Health Corporation study (n=440,590 adults) documented 63.4% of attending adults living with overweight or obesity, and 28.0–35.8% with obesity outright (the higher figure applying ethnicity-modified WHO thresholds).[10] UAE nationals carry 68.3% OAO prevalence. WHO age-standardised estimates put adult female obesity at 44.2% and adult male at 30.9% — well above regional averages. Foundayo (orforglipron) launched April 2026 via Metabolic.Health (Dr. Ihsan Almarzooqi's clinic-in-the-cloud platform); UAE was the second country in the world to approve Foundayo, days after FDA approval.[11] The patient cohort is in active formation right now — exactly when companion-product brand loyalty gets won. GLP-1 out-of-pocket cost is AED 744–2,000+/month (~USD 200–540), meaning the user base is structurally affluent and cash-paying.
The NZ-UAE CEPA was signed January 14, 2025 and entered force August 28, 2025 — New Zealand's first FTA with any GCC member. Under CEPA, 98.5% of NZ goods get duty-free access at entry-into-force (rising to 99% within three years); all dairy, red meat, horticulture, and industrial goods are duty-free immediately. NZ exports to UAE reached NZ$1.15 billion (USD 669M) in the year to September 2024, with dairy alone at USD 454M.[12] The UAE A2 Milk market is valued at USD 120M growing at 17.3% CAGR through 2029.[13] Comvita and Manuka Health have established GCC distribution. New Zealand Trade & Enterprise operates offices in both Dubai and Abu Dhabi, with a dedicated Made with Care UAE program providing introductions and importer networks. FernMark applies. The receptivity score of 3/3 is well-supported.
Federal Decree-Law No. 38 of 2024 created the Emirates Drug Establishment (EDE) as the unified federal regulator, replacing MOHAP for marketing authorisations, GMP certification, pharmacovigilance, and licensing. Effective December 29, 2025, EDE assumed 44 core services including dietary supplement registration.[14] For Nouri's planned vitamin/mineral + whey isolate SKUs with no medicinal claims, the primary path is Dubai Municipality's Montaji portal — typical timeline 12 working days to 4–6 weeks, fees AED 110–240 per product, 5-year registration validity.[15] The federal EDE path is required only if Nouri makes medicinal/restricted claims. Halal certification is mandatory: porcine gelatin in capsules is the single biggest haram risk, so Nouri should commit to HPMC/pullulan vegetable capsules from day one. FIANZ (in NZ) plus the federally-recognised ESMA Halal Mark (now under the Emirates Standards and Metrology Council/MoIAT) is the certification path. Bilingual English + Arabic labels are mandatory. Total entry investment: NZ$30K–60K plus local-agent ongoing share; 4–6 months end-to-end from initiation to first orders.
The UAE supplement retail landscape is pharmacy-dense (Aster, Life Pharmacy, BinSina, all carrying Holland & Barrett and GNC distribution) and brand-fragmented — no dominant GLP-1 companion player. The strategic partnership candidate is Metabolic.Health: the same Almarzooqi platform that brought Foundayo to the UAE operates a subscription weight-loss program ("Zone") combining wearables, telehealth coaching, and GLP-1 prescription. Co-promotion of Nouri as the nutritional-companion layer within Metabolic's Zone program would be the highest-leverage acquisition channel. DTC channels are mature: Noon (~5M active users), Amazon.ae (~6M), Carrefour Online, Lulu digital. Apple Pay, Google Pay, AED-pegged-to-USD payments. Critically: Hims & Hers / Eucalyptus has confirmed expansion to AU/UK/DE/JP/CA but NOT UAE — the GLP-1 companion DTC slot is not yet contested by the dominant Anglo-DTC operator.
Wave 2 — enter UAE 3–6 months after AU launch (i.e., 6–12 months post-NZ). Wait through Q2 2026 to let the EDE portal/document stabilisation complete; begin Halal certification (8–12 weeks via FIANZ + ESMA) and local-agent selection in parallel with AU launch. Pre-launch investments: Halal certification (NZ$10–25K); NZTE Dubai engagement + FernMark licence (NZ$800–10K/yr); Arabic + English bilingual labels (NZ$5–10K); local agent (medical-warehouse-licensed) selection from 3–5 candidates; strategic Metabolic.Health partnership conversation. Recommended soft-launch Q4 2026 / Q1 2027 with DTC + Noon + Amazon.ae rails operational and ESMA Halal Mark approved.
Headline: South Korea is the cleanest near-term Asian launch for a GLP-1 companion supplement. The entire ~400,000+ patient base is paying privately because national reimbursement is locked out, K-Wellness positioning maps directly onto Nouri's clean-label NZ provenance story, and Korean clinicians have publicly named muscle loss as the priority GLP-1 side effect — mapping precisely onto Nouri's whey isolate + vitamin/mineral system. The watch-out is closing competitive vacancy: Korea Ginseng Corp launched the GLPro Core line in 2025 positioning explicitly around GLP-1-adjacent blood-sugar control, and the window for explicit GLP-1 companion positioning is 12–18 months.
The numbers anchor the case. Doctors issued ~395,400 Wegovy prescriptions through the national Drug Utilization Review system between launch (October 15, 2024) and June 2025 — eight months. Monthly prescriptions surged from ~11,000 at launch to ~89,000 in May 2025; the 2025 monthly average has already topped 57,000.[16] IQVIA estimates Wegovy generated ₩213.3 billion (USD $154M) in H1 2025 revenue alone, capturing 82% of Korea's obesity drug market in Q2.[17] Mounjaro launched August 2025 at ~25% below Wegovy starter pricing, triggering a Novo Nordisk Wegovy price cut of 10–40%.[18] Grand View Research projects the SK GLP-1 weight-loss drugs market at $122.8M (2024) → $386.1M (2030), 16.7% CAGR.[19] Critically, reimbursement is zero and locked: national health insurance does not cover obesity-indication GLP-1s, and Korean pharma coverage describes reimbursement as "unlikely in the short term." Every GLP-1 user in Korea is paying ₩200–300K/month privately — already a premium self-pay healthcare consumer.
Korean adult obesity rate is structurally lower than Western markets (~34.4% with BMI ≥25, the Asian-adjusted threshold). But Wegovy launch behaviour reveals heavy off-label use for body-composition and aesthetic outcomes rather than morbid obesity — Korea's health ministry has had to publicly warn that the drugs should only be prescribed to BMI ≥30 or BMI ≥27 with comorbidity, and adolescent and pregnant-woman misuse have made national news. For Nouri this is a feature, not a bug: the SK GLP-1 cohort skews younger, more body-composition-focused, more aesthetic-driven — therefore more receptive to a clear-whey-protein + comprehensive-micronutrient companion than the Western "GLP-1 = severe obesity" archetype.
The KNZFTA has been in force since December 2015; by year 15 (2030), 97.8% of NZ exports to Korea will be duty-and-quota-free, with HS 2106.90 (formulated supplements) and HS 2936.xx (vitamins) in the preferential schedule. NZ is Korea's #5 export destination at 3.2%. But consumer-awareness is asymmetric: Korean shoppers know NZ premium dairy/honey out of proportion to overall trade volume. a2 Milk holds an active partnership with Yuhan Corporation (a major SK pharma/healthcare group); a2 publicly named South Korea as a named growth market in 2025 investor updates.[20] Organic a2 milk commands premium positioning in SK on clean-label / antibiotic-free / hormone-free signals — the exact provenance trust currency Nouri uses. Comvita operates 400+ retail stores/SIS across Asia with active FernMark licensing. The K-Wellness movement explicitly borrows from K-beauty's ingredient-provenance playbook, and NZ provenance maps cleanly onto that framework as a foreign-but-trusted analog.
Standard multivitamin + whey isolate falls under MFDS's Health Functional Food (HFF) "notified ingredients" pathway — the faster of two routes. No individual-ingredient approval is needed if Nouri's formulations stay within the published HFF Code (which covers vitamins, minerals, dietary fiber, protein, essential fatty acids). Realistic time-to-shelf: 3–6 months from kickoff to first cleared shipment, dominated by Foreign Food Facility Registration (the differential registration scheme, compulsory for HFF since 2024, accepts HACCP/GMP/ISO22000 certificates), Korean labeling, and finding a local agent. NZ is PIC/S member which functions as the de facto recognition basis. Local representative required — this is non-negotiable, so Nouri must either appoint a Korean agent/distributor (the a2 Milk-via-Yuhan model) or establish a Korean subsidiary. Disease prevention/treatment/cure claims are strictly prohibited; "supports lean muscle retention during weight management" is compliant and Korean media discourse already frames muscle loss as the priority GLP-1 risk, so the framing carries strong consumer signal.
South Korea offers Coupang (24.6M active customers, ~50% of all Korean adults, Rocket Delivery same-day/next-morning), Naver Smart Store (73.6% of Korean mobile shoppers' primary live commerce destination), and Kakao Shopping Live. Subscription supplements are normalized; Coupang and Kakao Healthcare operate AI-personalized supplement subscriptions with virtual pharmacist chatbots. The proven foreign-DTC-wellness-brand template is Lemme (Kourtney Kardashian): launched exclusively on Coupang in September 2025 with 13 SKUs as the brand's first SK channel.[21] KakaoPay, NaverPay, NICE Payments are universal among Korean consumers under 50. KNZFTA preferential tariffs apply.
Korea Ginseng Corp is the most aggressive mover. KGC launched GLPro Core and GLPro Doublecut in 2025, branded explicitly around blood-sugar control and body-fat reduction, leveraging endogenous-GLP-1-modulation language.[22] CJ Wellcare launched Fatdown Slimming Shot May 2025 (HCA / garcinia cambogia). Maeil Selex dominates SK protein. But none of these combine NZ provenance + whey isolate + comprehensive micronutrient system architecture + explicit muscle-preservation framing tied to the medically-recognized GLP-1 side effect. KGC's GLPro is positioned as alternative (replace the drug); Nouri's positioning is companion (support the drug). Different shelf, different intent. The MFDS uncovered fake "edible Wegovy" supplements worth ₩32.4B in 2024–2025 — bad for bad actors, but a strong validation of consumer demand for legitimate, evidence-led, clean-label GLP-1-adjacent supplementation.[23] Window to enter ahead of an incumbent GLP-1 companion launch: 12–18 months.
Wave 2 — enter SK in Q1 2027 (Q3 2026 prep, parallel with UAE). 6–12 months post-NZ launch. Engage Korean local-agent/distributor partner immediately; begin Foreign Food Facility Registration. Pre-launch investments: Korean trademark filings (Nouri wordmark + logo), FernMark Korean QR-verification surface, Korean-language label artwork with DRI recalculation for the ≥30% claim thresholds, KOL/KOC scouting list (wellness, K-pop-adjacent, body-composition-focused creators), Coupang seller account, Naver Smart Store business registration prep. Estimated regulatory entry investment $30K–80K ex-marketing.
Headline: Japan is the single most NZ-provenance-receptive market in Asia, and the addressable GLP-1 cohort is much larger than the reimbursed-patient count suggests — an extensive, well-documented off-label cosmetic-weight-loss demographic served by 67+ dermatology and cosmetic clinics nationwide, with telemedicine players (Juniper, Nihonbashi Clinic, elife) adding scale. Japan's total Nouri-addressable user base is plausibly 130,000–200,000 by end-2026 with strong premium-pricing tolerance. The watch-out is the heaviest regulatory + localization lift in the portfolio: FFC notification, Japanese-language labels, and a near-mandatory local fulfillment partner.
Japan's GLP-1 market splits into two essentially separate demographics. The reimbursed cohort: Wegovy was approved by MHLW November 2023 and listed under national health insurance from February 22, 2024 (first Asian country). Zepbound was approved late 2024, NHI-listed March 19, 2025.[24] Reimbursed criteria are stricter than US/EU (BMI ≥35, or BMI ≥27 with two weight-related comorbidities). Novo Nordisk's peak-share estimate is 100,000 patients generating ~USD 216M (32.8B JPY) market. The off-label cosmetic cohort is the real opportunity: a 2025 JMIR Formative Research study identified 67 clinics operating 87 dedicated off-label GLP-1 diet-promotion websites active as of August 2024, with clinic mix skewing dermatology (18.3%), cosmetic dermatology (17.5%), and internal medicine (15.8%). Ozempic pens retail at 22,000–33,000 JPY (~USD 150–225) vs. the 11,008 JPY insurance list — 200–300% markups indicating premium-willing cosmetic clientele.[25] MHLW publicly opposes this off-label use but enforcement is advisory, not prohibitive, and the practice continues to grow.
Japan is NZ's #4 export destination at 4.9% of total exports (~USD 2.3B). April 2025 monthly exports hit USD 490M, up 12% YoY. NZ is Japan's largest source of butter outside Japan itself; Japan is NZ's #2 cheese market by volume. a2 Milk Japan market projected to USD 866M by 2030 at 21.3% CAGR (2025–2030); Japan accounts for 6.7% of global a2 Milk revenue.[26] Zespri holds 98% market share for NZ kiwifruit during season, Japan is the second-largest export market globally, 32M trays sold in 2024 (1.7× growth over 11 years), 800 licensed Japanese growers.[27] Comvita has had a Japan office since 2002; Asia-Pacific dominates Manuka honey at 30.3% global share. FernMark holds trademark filings in 43 jurisdictions including Japan, with 46% global recognition and 44% purchase-intent lift. Japanese consumers exhibit a documented trust-via-provenance pattern, particularly strong for clean-label, additive-free, traceable-origin health products. "Made in NZ" is not a tagline in Japan — it is an unlock.
Japan's supplement regulation is a layered three-tier framework. Foods with Nutrient Function Claims (FNFC) is the simplest tier — covers 20 ingredients (1 fatty acid, 6 minerals, 13 vitamins) with pre-authorized claim wording. No notification required if claims stay within FNFC pre-authorized phrasing and dose levels. Nouri's multivitamin enters this route. Whey protein isolate enters as general food (no distinct supplement category). The Foods with Function Claims (FFC) tier is required only if Nouri wants premium GLP-1-companion function claims (muscle preservation, satiety, recovery). FFC requires 6+ month timeline, systematic literature review per PRISMA 2020, and (since April 1, 2025) 120-day pre-market notification for novel ingredients. GMP compliance has been mandatory since September 2024.[28] Time-to-market: general food + FNFC, 3–5 months; FFC notification for GLP-1-adjacent claim, 9–14 months. Total cost: JPY 8–25M (~USD $55K–170K). Japanese-language labels are mandatory; PMD Act prohibits drug-style efficacy claims with tight enforcement.
Japan's DTC supplement channel functions but at materially lower subscription penetration than Korea, Singapore, or even China CBEC. Rakuten and Amazon.co.jp capture dominant ecommerce share; both have strong supplement/wellness verticals. Drugstore market is USD 103.65B in 2023 projected USD 140.82B by 2029, with Matsumoto Kiyoshi (largest chain) and Welcia (2,667 stores) as anchor distribution. FUJIMI (Tricot) operates fully personalized 5-tablet daily-pack subscription at JPY 6,400/month; FANCL (Kirin-owned since June 2024 for ~USD 1.4B) dominates domestic premium DTC supplement space. Credit cards capture 71% of ecommerce transactions; JCB is the dominant local network. Distributor margins run 20–30%; multi-layer channels are still common. JETRO offers free business matching (TTPP database) — recommended first stop. The telemedicine clinic partnership opportunity is the highest-leverage acquisition channel: Nihonbashi Clinic, Juniper Japan, elife operate English-friendly online GLP-1 prescription with nationwide refrigerated Yamato delivery; co-promotion of Nouri as the post-prescription nutritional support, distributed through the same pipeline, bypasses the marketplace ranking war.
Japan dietary supplements market is USD 13.60B (2025) projected USD 16.48B by 2031 at 3.26% CAGR. No dedicated GLP-1 companion brand has emerged in Japan as of May 2026. Searches across Japanese trade press, regulatory database snapshots, and brand-name combinations return zero. The off-label cosmetic-clinic channel is operating without a branded nutritional companion product attached — patients are being prescribed GLP-1s at JPY 22K–33K/month markups and walking out without protein/vitamin/mineral support guidance beyond ad-hoc advice. This is the most striking vacancy of any market analyzed. Traditional weight-management supplement segment focuses on gentle non-stimulant pre-meal products (kidney bean extract, lactoferrin, kōso enzyme blends) — none formulated for the muscle-loss + micronutrient-deficiency physiological reality of GLP-1 users. Clear whey isolate held 55.32% of Japan's 2025 whey protein market, with clear-protein subcategory growing fastest — and no NZ-origin clear whey isolate brand has a meaningful Japan position.[29] Three open positions (premium clear whey + NZ provenance + GLP-1 companion) combine into one defensible launch.
Wave 3 — enter Japan 12–18 months post-NZ launch as country #3 after Australia and Korea. Phase 1 (months 9–18): FNFC-only multivitamin + general-food clear whey isolate, no FFC claims, channel via Amazon.co.jp and Rakuten Ichiba, parallel B2B2C partnership with 2–3 telemedicine GLP-1 clinics (Juniper Japan, Nihonbashi, elife). Phase 2 (months 18–24): file FFC notification for one Nouri-specific function claim, pursue Matsumoto Kiyoshi or Welcia drugstore pilot. Total Phase-1 entry budget: ~USD $100–150K. Critical strategic point: DTC-only viability above ~JPY 100M (USD $670K) annual Japan revenue is constrained by FFC notification requirements and customer expectations of domestic fulfillment — Japanese retail/pharmacy partnership becomes effectively mandatory at that scale.
Headline: Singapore is a small but unusually-clean market that punches far above its absolute size as Nouri's Southeast Asian bridgehead. The HSA framework requires no pre-market approval for health supplements, English labeling is sufficient, and a recently-signed NZ-Singapore Comprehensive Strategic Partnership (October 2025) plus AOTES Agreement on Trade in Essential Supplies (May 2026) create unprecedented bilateral trade tailwinds. Singapore's strategic value is the operational platform for a 650M-person Southeast Asia regional zone — Malaysia, Indonesia, Thailand, Vietnam, Philippines — not the 5.9M-resident standalone P&L.
Singapore's Ministry of Health National Population Health Survey 2024 reports obesity (BMI ≥30) at 12.7% of residents (up from 10.5% in 2019–2020) and 22.8% in the high-risk Asian BMI category (≥27.5).[30] Diabetes prevalence sits at 9.1% with ~700,000 adults living with diabetes (projected 780,000 by 2050). HSA-approved GLP-1 stack: Wegovy (approved 2023, 2025 cardiovascular indication expansion), Mounjaro KwikPen (HSA-approved June 2025), Ozempic, Saxenda, Rybelsus, Trulicity all registered.[31] Out-of-pocket pricing: SGD $350–500/month for Wegovy, SGD $500+ for Mounjaro. Pure private-pay market — public-sector subsidy does not cover obesity treatment. Cross-border medical-tourism dimension is real: Wegovy is not yet approved in Malaysia while Singapore has carried it since 2023, creating inbound prescription tourism from Indonesian and Malaysian high-net-worth patients. Singapore's effective GLP-1 patient pool exceeds the resident base.
Singapore was NZ's first-ever bilateral FTA partner (ANZSCEP, in force January 1, 2001, upgraded January 2020). The relationship was elevated to Comprehensive Strategic Partnership in October 2025 including a Strategic Food Partnership linking NZ MPI with Singapore SFA, plus electronic-certification arrangement for food/primary trade. On May 4, 2026, both nations signed the AOTES — the world's first legally binding bilateral pact to keep food, fuel, healthcare products, and chemical/construction materials flowing during supply crises — incorporated into the existing CEP.[32] Two-way trade hit NZD $11.07 billion in the year to June 2025. For a NZ supplement brand entering a small Asian market, this is unusually thick bilateral plumbing.
FairPrice Finest and Cold Storage (Singapore's two premium grocery chains) carry premium NZ brands. Comvita has long-established Singapore retail (regional HQ Hong Kong since 2007). a2 Milk is sold across Singapore retail. Fonterra brands (Anchor, Mainland, Anlene) are mass-market staples — though the August 2025 Fonterra divestiture of its consumer business to Lactalis for NZ$3.85B creates complexity around the future "NZ origin" branding of those specific brands. Manuka honey from multiple NZ brands is mainstream in pharmacy and grocery. FernMark Trust Codes QR provenance is explicitly called out by NZ Story as having highest demand in Southeast and East Asian markets. Singapore's bilingual English-Mandarin consumer base + high disposable income + strong Western health-and-wellness affinity aligns near-perfectly with FernMark + Made-in-NZ signals.
This is Singapore's single biggest "yes" signal for Nouri. HSA's health-supplement regime requires no pre-market approval, no licensing, no product-code declaration in TradeNet import permits. Health supplements are not subject to approval and licensing by HSA for their importation, manufacture, or sales — making Singapore one of the fastest time-to-market jurisdictions on earth (comparable to Hong Kong, dramatically faster than China Blue Hat or Japan FFC).[33] The Voluntary Notification Scheme (VNS) is recommended for credibility — 60 working day turnaround, signals seriousness to regional distributors, essentially free. HSA's October 29, 2025 Prohibited and Restricted Ingredients update sets quantitative caps on vitamins/minerals (Nouri must screen formulations) and heavy-metal/microbial limits. NZ is a PIC/S member; NZ Medsafe GMP certificates are accepted by HSA. English-language labeling is sufficient — zero localization burden vs Nouri's NZ/AU packs. Estimated lead time without VNS: 4–8 weeks (~SGD $15–30K). With VNS: add 60 working days (~SGD $25–50K total).
Singapore's health-supplement market sits at ~SGD $202.8M (Statista 2024) with broader food-supplement category at US$567.77M (2023) projected to US$747.26M by 2027. Roughly 52% of supplement transactions in Asia are now online. Shopee (HQ Singapore, parent Sea Limited, USD $16.8B revenue 2024) is the dominant marketplace; Lazada (Alibaba-owned) is #2.[34] DTC Shopify is well-supported. Comparable DTC supplement plays: Nano Singapore (digital-first GMP-certified), Ultimate Sup (Shopee Best Store 2021–2024), Nature's Farm, AG1 launched in Singapore April 2024, Eimele and JSHealth Vitamins (Australian) accessible cross-border.[35] The SEA-bridgehead opportunity is the strategic kicker: Shopee, Lazada, and Sea Limited are all HQ'd in Singapore; companies use Singapore as regional HQ for the 650M-person Southeast Asia zone; free-trade zones allow store-and-re-export without customs duties.
Eu Yan Sang International (Singapore-headquartered TCM-leaning), Blackmores (Australian), Brand's Suntory/Suntory Wellness Singapore, Bio-Life Science Group, Amway/Herbalife/USANA (MLM), GNC Holdings, Swisse, Nature's Farm, LAC Global, Kinohimitsu, Ocean Health, Watsons Singapore (pharmacy retail) are the incumbents. No identified Singapore-based or regional brand has explicitly positioned as a GLP-1 companion brand. Existing weight-management SKUs from Blackmores/Suntory/Eu Yan Sang are traditional metabolic/weight-loss support — none GLP-1-adjacent positioned. Critical: Hims & Hers / Eucalyptus is not yet in Singapore (confirmed footprint AU/UK/DE/JP; Singapore flagged as future-replication target but not announced). This is the window — Nouri can land in Singapore with a clean differentiated position ahead of Pilot/Juniper's Asia push. AG1 is the closest analog (daily foundational nutrition DTC subscription, English-native) but uses pea protein, not whey, and is not GLP-1-companion-positioned.
Wave 3 — enter Singapore 12–18 months post-NZ launch (parallel with Hong Kong + Japan), as part of the platform-plays wave. Pre-launch investments: HSA VNS dossier (start at month 0, lodge 60-day notification by month 3, SGD $25–50K); ACRA Singapore Pte Ltd entity (~SGD $5–10K); Singapore distributor / 3PL for bonded warehousing; FairPrice Finest / Cold Storage listing options (optional retail layer); English-labeled SKU (already done if Nouri's NZ/AU packs use English-only labeling — zero incremental cost); Shopee + Lazada storefronts plus standalone DTC site with SGD pricing + PayNow/credit card. Strategic ambition: treat Singapore as Year-1 entry + Year-2-3 regional springboard, target 3–5x revenue multiplication via SEA regional expansion off the same regulatory dossiers, supply chain, and brand assets.
Headline: Hong Kong is a small-but-premium DTC supplement market where every Nouri advantage compounds — NZ provenance, clean regulatory path, world-class payment/logistics, highest GLP-1 user wealth in the region. The strategic prize is not the 7.5M residents but the legitimate, regulator-friendly bridge into mainland China via Tmall Global CBEC and the formalised daigou network. The watch-out is the small absolute market: treat HK as standalone and the P&L story is thin; treat HK as the China bridge and the strategic ceiling is meaningfully higher.
HK has ~7.5M population with the highest per-capita GDP in Asia outside Singapore (US$54,079 in 2024). Cardiometabolic burden is substantial: 32.6% of adults aged 15–84 carry a BMI ≥25 (Population Health Survey 2020–22 — 26.4% female, 39.4% male). Diabetes prevalence is 8.5% combined self-reported + biochemically detected, rising to 19.0% in the 65–84 cohort.[36] The pivotal recent event is Novo Nordisk's official Wegovy launch in Hong Kong on November 3, 2025 — private clinics and selected pharmacies, indicated for adults BMI ≥27 with comorbidity.[37] HK private-clinic pricing is the highest in SE Asia: USD $1,050–1,600/month for Wegovy, USD $770–1,470/month for Mounjaro. Private health insurance coverage is patchy. The HKD 8,000–12,000/month out-of-pocket profile means HK GLP-1 patients are categorically a high-disposable-income cohort. Implied active GLP-1 user range: 30,000–80,000 patients — small absolute but highest annual companion-product willingness-to-pay in the region.
NZ exports to Hong Kong were US$739.28M in 2024. HK is consistently inside NZ's top-10 export destinations.[38] The NZ-Hong Kong, China CEP has been in force since 2011, with 2024 General Review, Investment Protocol, and Environment Cooperation Agreement. HK is already a free port. Three datapoints establish premium-NZ-brand dominance: Zespri — NZ led HK's fresh kiwifruit imports at US$80.0M in 2024, a 73.4% share, with NZ fruit exports growing 12.8% CAGR while broader HK fruit imports declined.[39] Comvita — HK offices since 2007, operates HK as regional hub for 18+ Asia-Pacific countries; sits on shelves in HKTVmall, SOGO, Mannings, Watsons; Asia-Pacific is >30.3% of global manuka honey market and Comvita holds ~54% of China manuka category.[40] a2 Milk — launched HK-specific stage 1–3 infant formula via cross-border ecommerce. FernMark filings cover HK and China; at Asia Fruit Logistica 2025 in HK, the NZ Avocado Growers Association explicitly built their booth narrative around FernMark to differentiate against larger Peruvian/Mexican/Australian competitors. HK consumers' supplement-purchasing behaviour weights transparency, certifications, and provenance heavily — both Mannings and Watsons have invested in QR-code ingredient transparency precisely because shoppers research before buying.
HK's regulatory ground is among the cleanest globally — if the product can stay inside the food classification and away from pharmaceutical/proprietary-Chinese-medicine boundaries. No pre-market approval, no registration dossier with the Department of Health for the food-classified path. Labeling per Cap. 132W is straightforward: ingredients list, energy + core nutrient panel, use-by date, name + address of HK-based manufacturer/packer/distributor, allergen disclosure (whey = milk allergen), English OR Traditional Chinese acceptable (recommended: bilingual front-of-pack with English ingredient list + Traditional Chinese product name and key call-outs). Claims discipline: no medicinal claims, no UMAO violations. Nutrient function claims allowed if scientifically grounded and meeting minimum-content thresholds. NZ MPI Risk Management Programmes carry strong weight with FEHD; while no formal mutual recognition like TTMRA exists, NZ's regulatory reputation is uncontested. A food-classified supplement can be shelf-ready in Hong Kong in 6–10 weeks end-to-end (label re-design + Traditional Chinese translation + freight + customs clearance + distributor onboarding). Cost is in single-digit thousands of NZD — orders of magnitude below TGA, MFDS, FFC/FOSHU, or Blue Hat.
This is the strategic prize. Tmall Global is Alibaba's cross-border ecommerce marketplace with 38% CBEC import market share, 46K+ brands from 90+ countries. Health supplements are exempt from Blue Hat registration when sold via Tmall Global; existing home-market certifications suffice. 6–12 weeks to launch, ~US$25,000 refundable security deposit.[41] Daigou flow — USD 81B industry — remains active though formalised, evolving toward livestream and content-led shopper-influencer models. HK historically functions as both a daigou source and a transit point. NZ-origin premium brands (a2 Milk, Comvita, Manuka Health) all have daigou exposure. Bonded-warehouse model: ship to Ningbo / Zhengzhou / Shenzhen / Guangzhou Free Trade Zone bonded warehouses; products clear into mainland China as personal imports. The HK retail + HK DTC + Tmall Global flagship + bonded warehouse + daigou amplification architecture is the single most important strategic feature of HK as a Nouri market.
HK online retail sales reached HK$27.5B in the first nine months of 2025; full-year ecommerce projected at US$5.34B in 2025 at 7.87% CAGR through 2029. Average Order Value is USD 111.79; per-shopper annual spend is USD 3,083, projected to USD 4,304 by 2027 — substantially above SE Asia averages. Faster Payment System (FPS) had 14.95M registered users by July 2024, with digital wallet penetration projected to hit 91% by 2026 (AlipayHK, WeChat Pay HK, Octopus/PayMe, FPS, credit cards). SF Express HK runs >100 self-operated network points and 939+ self-service locker kiosks — HKD 25 base rate for ≤1kg same-island next-day. Mannings (~300 stores, Dairy Farm) and Watsons (~170 stores, CK Hutchison) dominate offline supplement retail. Major incumbents on shelf: Swisse (most prominent imported premium brand), Comvita, a2 Milk formula, Blackmores, GNC, Holland & Barrett, Eu Yan Sang (~250 outlets), Vita Green, NMN specialists (Catalo, Supernine). Whey protein is sold via Marketplace, Citysuper, Wellcome, dedicated supplement stores, online — fragmented, no dominant brand. GLP-1 companion category is structurally empty: web searches return no HK-specific GLP-1 companion supplement brand. The Wegovy HK launch is six months old; the buyer cohort is brand-new and looking for support — textbook category-creation window. HK weight-management telehealth: SeedMedical Hong Kong (December 2025 evidence-based weight-management program launch), Trinity Medical, Pulse Clinic Hong Kong, Zoey HK — none has a packaged supplement-companion product.
Wave 3 — enter HK 12–18 months post-NZ launch, parallel with Singapore. The investments overlap significantly because Traditional Chinese localization completed for HK also de-risks Tmall Global. Sequence: Months 0–6 post-HK-launch, optimise HK standalone — DTC subscription unit economics, retail conversation initiation (Mannings/Watsons typically 6–9 months first-contact to shelf), clinic-partnership pilots (SeedMedical, Trinity, Pulse), Traditional Chinese localisation refined. Months 6–12, open Tmall Global flagship leveraging HK operational learnings; deploy bonded-warehouse model; engage daigou content-creator network. Months 12+, scale China presence with HK as regional brand-credibility hub and warehousing/logistics anchor. Watch-out: a2 Milk's daigou-channel mishandling is the cautionary tale — racing into Tmall Global without HK operational learning risks expensive China-channel mistakes (KOL selection, listing optimisation, daigou relationship management).
The 27 markets that did not surface in the recommended portfolio include several whose absolute GLP-1 user bases exceed any of the six selected. Section 10 lists the full disposition; this section provides substantive analysis of the eight most consequential — three named in the original expansion plan (United Kingdom, Canada, United States), one sequenced behind Hong Kong as the operational China bridge rather than entered directly (China mainland), and four large GLP-1 markets that require a non-NZ-anchored positioning architecture rather than the NZ-provenance lever that anchors the near-term six (Germany, India, Poland, Brazil). For each, the analysis identifies the screening result, the specific conditions under which entry would become viable, and the structural reasons the market is not in the near-term portfolio.
Headline: The UK is Europe's largest GLP-1 market and the most actively contested supplement-companion battleground outside the US. NZ-affinity is strong and regulatory ground is fast, but vacancy=1: incumbent telehealth platforms, Holland & Barrett's own-label push, and US-brand spillover mean the companion shelf is closing in months, not years.
A University College London analysis published 8 January 2026 estimated that 1.6 million UK adults used weight-loss medicines between early 2024 and 2025, with a further 3.3 million expressing intent to use them within the year — figures incorporated into the Greater London Authority Health Committee's March 2026 weight-loss medication report.[N1] The vast majority pay privately: Wegovy and Mounjaro entered the NHS through specialist weight-management services in 2023–2024 but on tightly restricted criteria. Private monthly costs run £99–£375 across Numan, Voy, Juniper (Eucalyptus/Hims & Hers), Pharmacy2U, Manual, Phlo, Piko and Second Nature.[N2] Holland & Barrett's 2026 customer research records that approximately 30% of UK adults are obese and 4% of households now include at least one GLP-1 user.[N3] The MHRA issued updated GLP-1 product information on 29 January 2026 outlining severe acute pancreatitis risk, with no impact on prescription volume.[N4] Eli Lilly's oral orforglipron is expected to clear MHRA approval in 2026, an inflection point retailers are already preparing for.
The NZ-UK Free Trade Agreement entered force 30 May 2023, eliminating tariffs on 99.5% of NZ exports at entry-into-force across wine, manuka honey, kiwifruit and most food and supplement HS codes.[N5] NZ honey exports to the UK grew 50% to NZ$57M in the year to June 2025 alone.[N6] Premium NZ-provenance brands have established UK retail presence — Manuka Doctor supplies Holland & Barrett directly,[N7] with Comvita, Manuka Health and a2 Milk holding distribution through grocery and specialty health channels. FernMark licensing applies in the UK under NZ Story's 43-jurisdiction trademark coverage. The provenance signal is established; the challenge is differentiation against incumbent NZ-premium brands already on shelf.
The UK's post-Brexit food supplement framework is among the fastest globally for compliant products. There is no mandatory pre-market approval — businesses register with local Environmental Health or Trading Standards and submit notification only for novel ingredients (post-May 1997).[N8] All health claims must align with the Great Britain Nutrition and Health Claims Register; only authorised claims (for example, "vitamin D contributes to the maintenance of normal bones") are permitted, with strict prohibition on disease-prevention/treatment claims.[N9] The MHRA's borderline-substance team adjudicates when supplement positioning approaches medical territory. The Advertising Standards Authority enforces marketing copy with active rulings against weight-management claim breaches through 2024–2026. For Nouri's vitamin/mineral + whey isolate stack, time-to-shelf is 4–8 weeks at trivial regulatory cost.
The UK companion-supplement shelf is the most crowded outside the US. Holland & Barrett (approximately 800 stores) announced a partnership with clinical weight-management provider Phlo in May 2026, signposting customers to GLP-1 services in-store and online alongside an own-brand "GLP-1 support stack" range — high-protein, high-fibre, magnesium, collagen, and vitamin D.[N3] H&B's 2026 trend predictions cite magnesium as the #1 searched ingredient of 2025 (8.5 million product searches), followed by collagen (6.2M), vitamin D (5.1M), and protein powder (4.4M) — precisely the formulation axes a GLP-1 companion product would occupy.[N10] Boots (~2,200 stores) operates a comparable supplement aisle. Telehealth incumbents — Numan, Voy, Juniper, Pharmacy2U, Manual, Phlo, Second Nature, Piko — collectively prescribe to the bulk of the 1.6M private-pay cohort, and several already signpost or bundle supplements. Hims & Hers' Juniper UK, acquired via the February 2026 USD $1.15B Eucalyptus deal,[N11] is the most credible near-term threat: H&H bundles supplements with GLP-1 subscriptions in the US, and UK integration is the natural next step. Australian and international spillover brands (JSHealth, Naturecan UK-origin GLP-1 bundle) are already accessible cross-border. No NZ-origin brand currently owns the GLP-1 companion shelf, but the unclaimed slot is narrowing month over month.
The UK does not clear the screening criteria for near-term entry because vacancy is closing fast and structural barriers to brand differentiation are real. Three conditions could change this assessment: (a) acquisition of a smaller UK-origin GLP-1 companion brand with existing H&B or Boots shelf positions; (b) a telehealth B2B2C partnership signed with Numan, Voy or Phlo before the Hims/Juniper integration matures, providing a captive supplement channel into the prescribing flow; or (c) a super-narrow niche the larger players are not chasing — post-discontinuation lean-mass preservation, sex- or age-specific cohorts, or oral-GLP-1-companion positioning ahead of orforglipron's MHRA approval. Absent one of those, the UK is a Year 3+ market entered as a second-mover into an established category. The orforglipron approval expected in 2026 will trigger another wave of category entry from H&B own-label, Boots, and the telehealth platforms — the window narrows further through year-end.
Headline: Canada has roughly three million adult GLP-1 users and was the first G7 country to authorise generic semaglutide in May 2026 — an inflection that will widen the user base substantially as prices fall. NZ-affinity is moderate (2/3) and regulatory ground is strong (3/3), but vacancy=1: US-brand spillover dominates Canadian supplement retail, and the Natural Product Number (NPN) lead time means Canada is structurally a Year 3+ market regardless of brand readiness.
A Canadian Medical Association survey indicates approximately three million Canadian adults are currently using GLP-1 drugs — Ozempic, Wegovy or Mounjaro — with many more deterred only by cost.[N12] Brand-name monthly prices run CAD $300–$400+. The pivotal recent event is generic entry: Health Canada approved its first generic semaglutide from Dr. Reddy's Laboratories (India), followed three days later by Apotex's Canadian-made version, in May 2026 — making Canada the first G7 country to authorise generic semaglutide.[N13] Under the pan-Canadian Pharmaceutical Alliance pricing structure, the first generic carries 75–85% of brand pricing; with a second on the market, both drop to ~50%; with three or more, the price falls to ~35% of brand-name Ozempic.[N14] Nine additional generic applications are pending with Health Canada. Critical constraint: Canadian generic semaglutide approvals so far cover only the Type 2 diabetes indication, not weight management — Wegovy remains patent-protected. Still, the off-label prescribing reality and the looming price collapse on the diabetes indication will detonate user growth across the cohort through 2026–2027. TELUS Health's 2025 employer drug benefits data shows Ozempic alone accounts for ~40% of diabetes drug spending — the single largest line item across all therapeutic categories.[N15]
NZ-Canada trade flows through the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), in force for both countries since December 2018, providing duty-free or preferential access on most supplement and food HS codes.[N16] NZ premium-brand presence in Canadian retail is established but lighter than in Australia, the UK, or Asia — Comvita and Manuka Health hold distribution through Costco Canada, Shoppers Drug Mart, and specialty health retailers; a2 Milk operates a limited Canadian distribution footprint. FernMark licensing applies. The provenance signal works but does not dominate; Canadian consumers default to US, European, and domestic premium brands in supplements more than to NZ provenance — reflected in the NZ=2 affinity score rather than the 3 that AU, UAE, Japan or HK receive.
Natural Health Products in Canada require an NPN (Natural Product Number) from the Natural and Non-prescription Health Products Directorate (NNHPD) before sale.[N17] Performance standards range from 60 days for Class I applications (medicinal ingredients fully attested to NNHPD Monographs) to 210 days for Class III novel-ingredient submissions; real-world wait times have historically run longer due to NNHPD backlogs. Site licences for foreign manufacturers are required, with Good Manufacturing Practices (NHP-GMPs) compliance verified before issuance. Bilingual English-French labelling is mandatory on all packaging. The total Canadian NHP industry generates approximately CAD $13B annually across ~90,000 licensed products since the framework's 2004 inception. For Nouri's vitamin/mineral + whey isolate stack, all medicinal ingredients map to existing NNHPD Monographs, qualifying for Class I treatment; total time-to-market is realistically 6–12 months including site licence, NPN issuance, French-language label artwork, and customs setup.
Canadian supplement retail is dominated by Shoppers Drug Mart (~1,300 stores under Loblaw Companies), Rexall, Costco Canada, Walmart Canada grocery health aisles, and DTC platforms led by Well.ca and Amazon.ca. US-brand spillover is the binding competitive reality: Nature Made (Pharmavite), Thorne, Vitamin Shoppe, Nature's Bounty, NOW Foods, and Garden of Life all operate established Canadian distribution — many sell US-formulated SKUs into Canada with bilingual relabelling. Domestic supplement leaders include Jamieson (the largest Canadian-owned brand, listed on TSX), Webber Naturals, Sisu, and Genuine Health. Telehealth GLP-1 access in Canada is led by Felix Health, which is operating a public waitlist for generic semaglutide access ahead of full availability;[N18] Maple Virtual Care and TELUS Health Pharmacy round out the prescribing-platform layer. WeightWatchers Canada operates the Sequence-comparable medication-plus-coaching subscription. No Canadian brand has yet launched an explicit GLP-1 companion product, but the supplement giants (Jamieson, Webber Naturals) have the distribution and formulation capability to enter quickly once category demand crystallises around generic semaglutide pricing.
Canada is a structurally Year 3+ market for Nouri. The NPN 6–12 month real-world lead time, combined with vacancy=1 from US-brand spillover, means Canada cannot be a first or second wave market regardless of brand readiness. The right operational play is to file the NPN now, completing the site licence and Class I application in parallel with Wave 1–2 launches, so the regulatory groundwork is in hand when generic semaglutide pricing detonates user growth in 2026–2027 and the companion category is forced open by 3M–4M+ active patients. Three conditions could pull Canada forward in the sequence: (a) earlier-than-expected weight-management indication on generic semaglutide; (b) a Felix or Maple telehealth supplement-bundling partnership signed early; or (c) acquisition of a smaller Canadian-origin GLP-1-adjacent supplement brand with NPN-in-hand and existing distribution. None changes the fundamental calculus that Canada follows AU + UAE + SK as the portfolio's first three priorities.
Headline: The US is the largest GLP-1 market in the world by an order of magnitude. It was kept as Marginal in the screening rather than fully rejected because absolute market size warrants visibility in any serious expansion analysis — but the recommendation is unambiguous: do not pursue independent entry. Vacancy=0 is a hard structural fail: the GLP-1 companion shelf is already locked by at least eight well-capitalised brands operating at national scale.
IQVIA reported 11 million unique GLP-1 patients in the US as of Q2 2025 across all indications, with prescription-class promotional spend exceeding USD $7 billion by mid-2025.[N19] The RAND American Life Panel (2025, n=8,793) found 11.8% of US adults reported GLP-1 use, peaking among women aged 50–64 where one in five had ever used a GLP-1.[N20] J.P. Morgan Global Research projects the active US GLP-1 cohort to reach 25 million by 2030 — up from ~10M in 2025, 6M in 2024, and 5M in 2023 — driven by oral GLP-1 launches (orforglipron approved late 2025; a second oral product expected 2026), generic competition, and expanded coverage.[N21] The Center for Medicare and Medicaid Services BALANCE pilot announced late 2025 introduces a $50/month Medicare out-of-pocket cap on GLP-1s, fundamentally shifting the demographic from affluent self-pay into mass-market reimbursed populations.[N22] Patient persistence is improving: 63% of Wegovy/Zepbound starters from early 2024 remained on therapy at 12 months, up from 40% the year prior.[N21]
NZ premium-brand presence in the US is meaningful but does not dominate consumer mindshare in the supplement category. Comvita US sells manuka honey at scale through Whole Foods, Sprouts, Target, and Amazon; a2 Milk US operates a national premium-dairy line through Whole Foods, Sprouts, Walmart and Costco; Zespri SunGold kiwifruit holds meaningful retail presence in California and the Northeast. FernMark licensing applies under NZ Story's US trademark coverage. None of this provenance signal translates strongly to a GLP-1 companion supplement positioning — American consumers in wellness default to US-formulated, clinically-positioned, and celebrity- or telehealth-bundled brands. The NZ provenance lever that anchors the Australia, UAE, and Japan cases provides limited differentiation on the US shelf.
The US GLP-1 companion supplement shelf is occupied at scale by at least eight branded operators:
The US DTC supplement market runs on Amazon (~50% of online supplement sales), Shopify-direct subscription, retail (Whole Foods, Sprouts, Target premium aisle, Costco, Walmart), and telehealth-bundling (Hims, Ro, Sequence, Whole Health Rx). The binding constraint is not channel access but customer acquisition economics: US health-and-wellness CAC routinely runs USD $75–$200 blended for category leaders; new entrants without category recognition, clinical authority, or celebrity association face CACs that compress unit economics beyond viability at the price points where companion-positioned products clear ($40–$80 monthly). The eight incumbents above all carry differentiating moats — retail shelf, telehealth pipeline, celebrity, MLM network, or programme bundling — that an independent NZ-origin DTC entrant cannot replicate.
Independent NZ-origin entry into the US GLP-1 companion category is not viable at Nouri's current scale. The honest path forward is one of: (a) acquisition of an existing US brand with shelf positions or telehealth distribution — the Lemme-style premium-celebrity tier or a mid-market dietitian-led brand would be the logical archetypes; (b) telehealth bundling deal with a non-Hims, non-Ro prescribing platform that has not yet locked supplement supply (a narrowing field); or (c) super-narrow niche positioning targeting a specific cohort the giants are not chasing — post-discontinuation lean-mass preservation, vegetarian/vegan GLP-1 users, men's-specific cohorts. Even with one of those moves, US entry would require dedicated US team, dedicated US capital, and a 24–36 month timeline. The strategically correct read is that the US is a market Nouri enters from strength after the international portfolio is established, not as part of the initial expansion. The conventional view that US entry is "deliberately avoided" is confirmed by the structural data.
Headline: Mainland China is the single largest GLP-1 patient pool on earth, with NZ-affinity scoring 3/3 — the strongest non-Anglosphere market for premium NZ provenance. The regulatory score of 1/3 reflects the domestic Blue Hat barrier on Health Food (Bao Jian Shi Pin) general-trade registration, but Tmall Global cross-border ecommerce (CBEC) bypasses Blue Hat entirely. The reason China is not in the near-term portfolio is portfolio sequencing, not market viability: Hong Kong is the operational bridge, and direct China-CBEC entry becomes viable in Year 2–3 after HK is established.
China has more people with type 2 diabetes and obesity than any country in the world — over half of Chinese adults were overweight or obese as of 2022. NMPA approved Wegovy for chronic weight management in June 2024 (marketed locally as NovoCare) and Mounjaro/MuFengDa in 2024; Novo Nordisk China Ozempic sales reached USD $693 million in 2024, more than doubling year-on-year.[N24] Clarivate estimates the Mainland China GLP-1 therapeutic market at USD $1.7 billion in 2023 with continued strong growth.[N25] The competitive landscape detonated on 20 March 2024 when semaglutide lost patent protection in China, clearing the way for domestic biosimilars from Hengrui Pharmaceutical, Sciwing Biosciences and others.[N26] In June 2025, Innovent Biologics' mazdutide — the world's first dual GCG/GLP-1 receptor agonist, licensed from Eli Lilly — received NMPA approval for chronic weight management based on the GLORY-1 Phase 3 trial in Chinese adults. Mazdutide is projected to reach USD $1.3 billion in 2030 sales.[N27] Hengrui's ribupatide reported Phase 3 efficacy exceeding semaglutide; the active Chinese GLP-1 cohort by end-2026 will likely exceed 5–10 million patients.
NZ provenance carries unusually high consumer recognition in mainland China relative to its absolute trade share. Comvita holds approximately 54% of the China manuka honey category and operates a Shanghai subsidiary; Asia-Pacific represents over 30.3% of the global manuka honey market with mainland China as the largest single contributor. a2 Milk sells China-specific Smart Carton infant formula via Tmall Global cross-border ecommerce and the formalised daigou network. Zespri exports significant kiwifruit volumes to China across multiple PRC-listed entry points. FernMark trademark filings cover China, with the strongest Asian recognition concentrated in Tier-1 cities (Shanghai, Beijing, Shenzhen, Guangzhou). The provenance trust signal is strong — this is the highest NZ-affinity score of any market outside Australia, UAE, Japan, and Hong Kong.
China's supplement regulation operates on two parallel tracks with radically different friction:
The CBEC channel was explicitly designed to bypass domestic regulatory friction for imported premium goods. For Nouri, this means China-CBEC entry follows the same regulatory dossier as Hong Kong (no NMPA Blue Hat submission required), bilingual English/Simplified-Chinese label artwork, and bonded-warehouse logistics setup.
The CBEC + daigou architecture is the strategic prize. Tmall Global (Alibaba) holds approximately 38% of China's CBEC import market share with 46,000+ brands from 90+ countries. JD Worldwide and Kaola (NetEase) compete for the same imported-premium consumer. The daigou personal-shopper economy — estimated at USD $81 billion industry-wide — remains active though formalised, evolving toward livestream-led KOL formats on Xiaohongshu (RED) and Douyin. NZ-origin premium brands (a2 Milk, Comvita, Manuka Health) all have substantial daigou exposure. Domestic supplement giants include BY-HEALTH (汤臣倍健), Infinitus, Tongrentang, and Tasly; none yet operates an explicit GLP-1 companion brand line. The competitive vacancy in the GLP-1 companion-via-CBEC segment is open.
Mainland China is structurally accessible via CBEC but is not in the near-term portfolio for a single reason: portfolio sequencing. The Hong Kong recommendation in this portfolio explicitly positions HK as the China bridge — HK retail establishes brand credibility, Traditional Chinese label work de-risks Simplified Chinese localisation, HK operational learnings (KOL selection, listing optimisation, daigou relationship management) compound forward into Tmall Global flagship setup. Entering China-CBEC directly without HK operational foundation risks expensive channel mistakes — a2 Milk's daigou-channel mishandling is the documented cautionary tale. The correct sequence is HK Wave 3 (Year 1) → China-CBEC follow-on (Year 2–3), sharing the same Traditional/Simplified Chinese assets, regulatory dossiers, and bonded-warehouse logistics. China is not rejected — it is sequenced.
Headline: Germany is the largest continental EU GLP-1 market and Europe's biggest pharmaceutical market overall. NZ-affinity scores 1/3: German consumers respond strongly to provenance signals, but those signals are Alpine, Bavarian, or organic-certified (Bioland, Demeter), not Aotearoa. The implication is that German entry leads with pharmacy-channel credibility and clinical positioning rather than the NZ-provenance lever that anchors AU/UAE/Japan/HK — viable as a later wave under that adjusted positioning, with the restrictive Heilmittelwerbegesetz (HWG) advertising law as the additional discipline.
Wegovy launched in Germany in mid-2023 as Novo Nordisk's third European launch territory, with Germany being the EU's largest pharmaceutical market.[N28] Approximately 52.1% of German adults are overweight. Mounjaro entered the German market for Type 2 diabetes; Eli Lilly opted in 2025 for confidential discount pricing under the new Medical Research Act — the first manufacturer to do so.[N29] German public health insurance (statutory Krankenkasse) excludes weight-loss drugs as lifestyle treatments, with a narrow exception introduced in early 2024 for Wegovy in patients with serious cardiovascular obesity risk. Monthly private-pay costs run ~€300 for Wegovy 2.4mg and ~€350 for Mounjaro 15mg.[N30] Total German GLP-1 sales are projected to more than double to over €700 million by 2030. Distribution flows through online pharmacies (DocMorris with ~10 million active customers, Shop Apotheke, Zur Rose) operating under the eRezept digital prescription system, plus ~18,000 physical Apotheken nationally.[N31]
Made-in-NZ scores 1/3 because German consumer trust in premium provenance is concentrated on Alpine, Bavarian, organic-certified (Bioland, Demeter), and clinical-pharmacy signals — not on Aotearoa provenance. Comvita and Manuka Health have limited German retail presence; a2 Milk has minimal continental EU footprint; FernMark recognition in Germany is near-zero. The NZ-Anglosphere/NZ-Gulf/NZ-Asia premium-brand precedent does not transfer. A Germany entry therefore leads with a different positioning architecture: organic certification (Bioland/Demeter), EU-permissible clinical authority, ingredient-origin storytelling that resonates with Alpine or Nordic premium positioning, or pharmacy-channel B2B2C credibility. That is meaningfully different work than the NZ-provenance launches in AU/UAE/Japan/HK, and may warrant a Germany-specific brand variant rather than the Anglo-Pacific NZ-Nouri identity — but it does not foreclose the market. Germany is the largest continental EU GLP-1 market and a real Year 3+ option under the adjusted positioning.
EU food supplement framework applies via the Bundesinstitut für Risikobewertung (BfR) and Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) notification process — comparatively fast (60–90 day notification, no pre-market approval). The harder constraint is the Heilmittelwerbegesetz (HWG), Germany's strict pharmaceutical advertising law, which severely restricts health claims on supplements and adjacent products. EU Nutrition and Health Claims Regulation 1924/2006 layers additional discipline. German-language labels mandatory. The combined regulatory and marketing-claim regime is among the strictest in Europe for weight-management-adjacent positioning — meaning even a viable Germany entry must navigate substantially tighter copy constraints than the AU, UAE, or HK markets.
Pharmacy is the dominant German supplement channel — online pharmacies (mySpring, DocMorris, Shop Apotheke, Aliva) plus ~18,000 physical Apotheken. Drugstore chains (DM-drogerie markt with 4,000+ stores, Rossmann ~2,200 stores) carry mid-market supplement ranges. Amazon.de is the dominant DTC channel for non-pharmacy supplements. Competitive incumbents include Orthomol (Germany's premium supplement leader, pharmacy-exclusive distribution), Doppelherz (Queisser Pharma), Abtei, Tetesept, Hermes Arzneimittel, and Pure Encapsulations DE. The Eucalyptus-owned Juniper brand operates Germany alongside the UK and Japan, and post-Hims acquisition is the most credible near-term entrant to integrated GLP-1 + supplement bundling on the German market.[N11] No domestic German brand has yet launched an explicit GLP-1 companion product, but Orthomol's pharmacy-channel dominance makes it the obvious incumbent threat once category demand crystallises.
Germany is sequenced behind the Foundation Six on positioning architecture and claims-regime discipline, not on market size or product fit. Three positioning architectures could move it forward in the queue: (a) an organic-certified anchor (Bioland/Demeter) or clinical-authority anchor replacing the NZ-provenance lever — effectively a Germany-specific brand variant rather than the Anglo-Pacific NZ-Nouri identity; (b) a pharmacy B2B2C partnership with a major Apotheken chain or a pharmacy-distribution platform like Sanacorp, providing professional-channel credibility that bypasses consumer brand recognition; or (c) acquisition of an existing German supplement brand with pharmacy shelf positions and HWG-compliant marketing infrastructure. The natural revisit point is Year 3+ after Singapore demonstrates the SEA cascade model, providing a template for non-NZ-anchored regional entries — Germany is a large and growing market that fits the product's underlying merits (formulation quality, clinical positioning, ingredient story), just not under the NZ-provenance positioning that anchors the near-term six.
Headline: India's GLP-1 patient pool is already large and will detonate in 2026–2027 as multiple domestic generic manufacturers launch post-patent semaglutide. NZ-affinity scores 1/3: premium NZ-brand recognition is concentrated in metro-elite cohorts (Tier-1 cities, English-first, high household income) rather than spread across the mass market. India's near-term Nouri-addressable TAM is therefore the metro-elite tier — substantial in absolute terms, but a different unit-economic shape than the AU/UAE/Japan launches, and reachable through clinical-authority and premium-imported-wellness positioning at least as much as the NZ-provenance lever specifically.
India approved Mounjaro in March 2025 (launched April 2025) at INR 14,000–17,500/month and Wegovy in June 2025 (launched July 2025) at INR 17,345–24,280/month — both private-pay, with no public reimbursement.[N32] The pivotal event is semaglutide patent expiry in India scheduled for March 2026, after which domestic generic manufacturers (Sun Pharma, Cipla, Dr. Reddy's, Lupin, Zydus, Biocon) have signalled rapid generic launches that will collapse pricing toward Rs 5,000–10,000/month. The active GLP-1 cohort is concentrated in metro India (Bangalore, Mumbai, Delhi, Hyderabad, Chennai) where private-pay willingness is highest; post-generic launch the cohort is projected to expand into Tier-2 cities and reach 10–25 million patients by 2028–2030.
NZ-India trade flows through bilateral cooperation but without a comprehensive free trade agreement (negotiations ongoing). NZ premium-brand presence in India is concentrated in cross-border ecommerce: Comvita on Amazon.in, FernMark recognition limited to metro-elite consumer segments, a2 Milk's India entry is recent and small-scale. India's premium-supplement willingness-to-pay is bifurcated: Tier-1 metro elite consumers (~5–10 million households, INR 25L+/year income) sustain INR 4,000–8,000/month supplement spending for imported brands like Thorne, Designs for Health, and Pure Encapsulations; the broader Indian premium-supplement market caps at INR 1,500–3,000/month even for serious cohorts. NZ-provenance is one positioning option within the metro-elite tier; clinical-authority positioning (pharmaceutical-grade evidence, GP/specialist endorsement) and premium-imported-wellness positioning (Tier-1 city HNW lifestyle channels — Nykaa, metro telehealth platforms, Tier-1 city pharmacy retail) may reach broader segments of the same cohort under different storytelling. The addressable cohort for any premium GLP-1 companion is narrower than the headline patient-pool figures suggest, but the cohort itself is substantial.
India regulates supplements through the Food Safety and Standards Authority of India (FSSAI) under the FSS Act 2006 and the Health Supplements and Nutraceuticals Regulations 2022. FSSAI nutraceutical product registration typically takes 6–9 months and is moderately rigorous. The Advertising Standards Council of India (ASCI) enforces strict scrutiny on weight-loss claims, particularly post-2024 crackdowns on misleading wellness advertising. The Drugs Controller General of India (DCGI) vs FSSAI jurisdictional boundary on borderline-medicinal supplements remains evolving. English plus a regional language label requirements apply; manufacturing-origin documentation must be apostilled. Total entry cost is moderate (~USD $20–40K) for a clean vitamin/mineral + protein stack but the marketing-claim navigation is the gating exercise.
Indian supplement distribution flows through pharmacy chains (Apollo Pharmacy, MedPlus, Wellness Forever, NetMeds, 1mg), e-commerce (Flipkart, Amazon.in, BigBasket, Nykaa), and growing DTC subscription brands (HealthKart, MuscleBlaze, Setu Nutrition, Carbamide Forte, Plix Life, Pilgrim). GNC India and Optimum Nutrition India hold the premium-imported tier. The metro-elite telehealth GLP-1 channel is led by Mars by GHC (Good Glamm Group's health vertical, bundling telehealth with supplements), Setu, and Apollo 24/7. No Indian brand has yet launched an explicit GLP-1 companion product, but the supplement giants (HealthKart, MuscleBlaze) have the distribution to enter quickly once generic semaglutide pricing detonates the user base.
India's GLP-1 user base is large and growing fast; the near-term Nouri-addressable cohort is the metro-elite tier, reachable via premium-imported-wellness or clinical-authority positioning more than the broad-base NZ-provenance lever. Two operational shapes make this viable: (a) a metro-elite positioning architecture (premium-imported wellness, clinical-authority anchored) priced at INR 4,000–8,000/month and distributed through Nykaa, premium pharmacy retail, and metro-elite telehealth platforms; or (b) a strategic partnership with a major Indian supplement player (HealthKart, MuscleBlaze) where Nouri operates as a premium tier rather than a mass entrant. The natural revisit point is Year 3+ once the post-patent generic GLP-1 user base has matured and metro-elite cohorts have stabilised willingness-to-pay benchmarks — India is a different unit-economic shape than the near-term six, not a market the brand thesis breaks on.
Headline: Poland is the largest GLP-1 market by spending in continental EU by some measures — ~PLN 3.4 billion in 2025 GLP-1 spend. NZ-affinity scores 0/3: Polish consumer trust runs through pharmacy recommendation, doctor authority, and clinical evidence rather than country-of-origin provenance signals. The implication is straightforward — Poland entry leads with pharmacy and clinical positioning rather than the NZ-provenance lever, viable as a Year 3+ market under that adjusted positioning architecture.
Poland's GLP-1 spend reached approximately PLN 3.4 billion in 2025 across Wegovy, Mounjaro, Ozempic, and Saxenda, with private-pay dominant (Polish NFZ public reimbursement excludes obesity indication). Major Polish telehealth GLP-1 providers include Doctor.One, Telemedi, and Mediclub. The Polish private-pay user base is concentrated in Warsaw, Krakow, Wroclaw, and Poznan affluent cohorts; monthly costs run PLN 800–1,500 (USD $200–380).
Polish consumer trust in premium supplements is concentrated on pharmacy recommendation, doctor authority, and clinical evidence — not on country-of-origin provenance signals. Comvita has no meaningful Polish retail presence; a2 Milk is absent; FernMark recognition is essentially zero in Polish consumer research. NZ-Poland trade flow is minimal. The premium-supplement category in Poland is led by domestic giants (Olimp, Aflofarm) and pan-EU brands distributed through Polish pharmacy networks. A Polish entry therefore leads with pharmacy-channel credibility, clinical-evidence positioning, or local-manufacturing partnership rather than the NZ-provenance lever that anchors AU/UAE/Japan/HK — the product's underlying merits (formulation quality, clinical positioning, ingredient story) carry through, but the storytelling axis is different.
EU food supplement framework applies via Poland's Główny Inspektorat Sanitarny (GIS) — the Chief Sanitary Inspectorate — under EU Directive 2002/46/EC. Notification rather than pre-market approval; typical notification 30–60 days. EU Nutrition and Health Claims Regulation 1924/2006 applies; Polish-language labels mandatory. Regulatory friction is low — in stark contrast to the NZ-affinity gap.
Polish supplement retail is dominated by pharmacy chains (DOZ, Super-Pharm, Apteka Gemini, Apteka Dr. Max), the drogerie chain Rossmann Poland (1,500+ stores), and the e-commerce giant Allegro (the Polish equivalent of Amazon, with 80%+ Polish e-commerce share). Polish supplement leaders include Olimp, Trec Nutrition, Aflofarm, USP Zdrowie, and NaturalProtein — collectively dominating the protein and sports-nutrition tier. GLP-1-companion-positioned products have not yet emerged from Polish manufacturers, but the supplement category is professionally distributed and incumbent-led.
Poland is sequenced behind the Foundation Six on positioning architecture, not on market size or regulatory friction — the underlying GLP-1 momentum is among the strongest in continental EU. Entry requires a different consumer-trust axis: clinical positioning, pharmacy-channel B2B2C, EU-permissible-claims authority, or partnership with a Polish manufacturer for local production. The natural revisit point is Year 3+ once the Foundation Six is operating at scale and the brand can carry a non-NZ-anchored positioning variant, or if a pan-EU bridgehead emerges that pulls Poland into the Foundation Six's slipstream. Poland is a large and growing market that requires a different positioning architecture than the NZ-provenance lever — a sequencing question, not a market-quality verdict.
Headline: Brazil holds approximately 60% of the Latin American GLP-1 market and is the largest single LATAM patient pool by an order of magnitude. NZ-affinity scores 0/3: NZ provenance does not register with Brazilian consumers at scale. Brazil entry therefore leads with a Portuguese-language clinical/celebrity-led positioning architecture — a brand-architecture choice that opens the market under different storytelling than the NZ-provenance lever, not a market-quality verdict.
Brazil's GLP-1 market is led by Novo Nordisk Brasil and Eli Lilly Brazil, with Ozempic in widespread use for both diabetes and off-label obesity. SUS (the public health system) largely does not reimburse for obesity indication, putting most users in the private-pay segment. The pivotal recent dynamic was the collapse of the Brazilian compounding pharmacy ("manipulação") market for semaglutide after ANVISA regulatory clamp-down in 2024–2025 forced patients onto branded products. Mounjaro launched in Brazil in 2024. Total active GLP-1 cohort is estimated at 1.5–3 million patients, growing rapidly across Tier-1 Brazilian cities.
NZ-Brazil trade flows are minimal; no premium NZ brand has meaningful Brazilian retail presence; FernMark recognition is essentially zero. Brazilian premium-supplement consumer trust concentrates on three architectures: US-formulated imports, pharmaceutical-grade clinical brands, and celebrity-endorsed wellness positioning. Made-in-NZ does not transfer as the lead positioning lever; the product's underlying merits (formulation quality, clinical positioning, ingredient story) can still compete in Brazil under any of those three Brazilian-resonant architectures.
Brazil regulates supplements through ANVISA under RDC 243/2018 (dietary supplements) and RDC 240/2018 (vitamins and minerals), with Portuguese-language labelling mandatory. Registration timelines run 6–18 months depending on category complexity; total cost typically USD $40–80K for a multi-SKU registration. Brazilian-origin manufacturing-equivalence documentation, GMP certification, and apostilled supporting documents are required.
Brazilian supplement distribution flows through Mercado Livre (LATAM's Amazon equivalent), Magazine Luiza, the dominant pharmacy chains RaiaDrogasil (Drogasil + Droga Raia, ~3,000 stores), Pacheco, and Pague Menos, plus the compounding-pharmacy network (~40,000 manipulação pharmacies, with custom-formula competition for branded supplements). Brazilian supplement leaders include Growth Supplements, Integral Médica, Atlhetica Nutrition, Probiotica, Vitafor, plus pharmaceutical giants Aché and EMS with consumer-health divisions. Telehealth GLP-1 access is led by Conexa, Memed, Hello Saude, Dr. Consulta. No Brazilian brand has yet launched a dedicated GLP-1 companion product, but the supplement giants have the distribution to enter quickly.
Brazil's absolute GLP-1 market size is significant and growing; the entry question is brand-architecture, not market-quality. Two operational shapes make Brazil viable: (a) acquisition or partnership with a Brazilian supplement brand carrying existing pharmacy and Mercado Livre distribution, with Nouri product underneath the local brand-front; or (b) a Portuguese-language clinical-authority or celebrity-endorsed positioning variant — a different storytelling architecture than the NZ-provenance lever, but resonant with Brazilian consumer trust mechanisms. The natural revisit point is Year 3+ once the Foundation Six is at scale and the brand can carry a positioning variant suited to LATAM consumer-trust architectures. Brazil is sequenced behind the near-term six on positioning architecture, not on the structural opportunity — which is among the largest single-market opportunities globally.
The analysis's discipline is visible in how it sequences markets outside the near-term six. Three patterns dominate:
UK, Canada, and the Gulf were named in the initial expansion plan as planned targets. The screening result: UK and Canada do not clear, and only UAE clears in the Gulf.
| Market | Why it doesn't clear | Composite |
|---|---|---|
| United Kingdom | Vacancy=1. Companion category is already crowded with Numan, Voy, Juniper (now Hims-owned), Therapie Clinic, plus US-brand imports. The UK is the highest absolute GLP-1 market in Europe with strong NZ-affinity and fast regulatory ground — but the GLP-1 companion shelf is largely taken, and the brand will compete head-on with telehealth-prescriber-bundled supplements. Marginal entry possible but lower expected ROI than the six selected markets. | 13 (Marginal) |
| Canada | Vacancy=1. US-brand spillover dominates Canadian retail (Nature Made, Thorne, Vitamin Shoppe operate Canadian distribution); the Health Canada NPN pathway also requires 12–18 month lead time — meaning Canada cannot be a near-term move regardless. Better positioned as Year 3–4 expansion after the portfolio is established. | 12 (Marginal) |
| Saudi Arabia | Regulatory=1. Strict claims regime + 6-month MOH timeline for herbal-route registration + sensitivity to GLP-1-adjacent positioning under Saudi advertising rules. Possible as follow-on to UAE if Halal-certified product proves out in UAE first. | 11 (Marginal) |
| Other GCC (Kuwait, Qatar) | GLP-1=1. Population scale + NZ-GCC FTA inferred affinity, but absolute GLP-1 volumes thin. Worth re-examining as GCC adjacencies if UAE proceeds. | 9 (Marginal) |
Made-in-NZ provenance is a positioning lever the recommended portfolio leans into where it already lands — Australia, UAE, Japan, Singapore, Hong Kong, and (at 2/3) South Korea. Markets where NZ-affinity is weaker — across continental EU, much of LATAM, and parts of South Asia — retain their underlying GLP-1 market quality but require a different positioning architecture than the Aotearoa-provenance lever. The table below names the largest of those markets and what the alternative positioning architecture looks like in each:
| Market | GLP-1 strength | Positioning architecture required for entry |
|---|---|---|
| Poland | PLN 3.4 billion in 2025 GLP-1 spend; high YoY growth | Pharmacy-channel B2B2C credibility + clinical-evidence positioning (NZ premium-brand awareness near-zero); subscription-DTC stack adapted to Allegro-dominated retail |
| Brazil | 60% of LATAM GLP-1 market | Portuguese-language clinical-authority or celebrity-led positioning (NZ awareness negligible); ANVISA 6–18 month registration cycle; subscription model adapted to Mercado Livre dynamics |
| India | Massive patient pool; generic semaglutide post-March 2026 patent expiry | Metro-elite cohort targeting via premium-imported-wellness positioning (NZ awareness metro-niche only); FSSAI nutraceutical registration + ASCI advertising discipline; pricing matched to bifurcated WTP |
| Mexico | Sizeable market; semaglutide expanding | Local-market positioning architecture (NZ retail visibility near-zero); COFEPRIS 6–12 month registration + Spanish labeling; channel build through Walmart/Soriana/Mercado Libre |
| Turkey, Argentina | Active GLP-1 markets | Local-market positioning + FX-tolerant unit economics (NZ awareness negligible; FX volatility breaks subscription) |
| France, Germany, Italy, Spain | EU's largest GLP-1 markets | Pharmacy-channel B2B2C + EU-permissible-claims clinical positioning (NZ presence thin, NZ=1 across continental EU); subscription-supplement adoption lower than UK/Asia; restrictive claim language regimes |
These are reasoned sequencing decisions. Each market remains commercially viable on the product's underlying merits — formulation, clinical positioning, ingredient story — and the table above names what the brand-architecture and operational shape would look like in each. What differs from the near-term six is the storytelling axis, not the product.
The United States is the largest GLP-1 market in the world and was kept as Marginal rather than fully rejected because absolute market size warrants visibility in any serious expansion analysis. But the recommendation is unambiguous: do not pursue independent entry. Vacancy=0 is a hard fail — the GLP-1 companion shelf is locked by Vitamin Shoppe (Whole Health Rx + 750+ stores private label launched March 2025), Nature Made (Pharmavite's GLP-1 Companion Health Pack), Thorne, Lemme (Kourtney Kardashian), Herbalife, Supergut, WeightWatchers (Sequence partnership), and Hims/Ro (telehealth-bundled). The screening confirms the conventional view that US entry is structurally locked at the companion-supplement level.
Three markets cleared the screening gate but were ranked below the top six selected for deep-dive: Ireland (composite 11; strong EU regulatory bridge but small absolute market and pharmacy-channel-dominated), Taiwan (composite 11; strong NZ-affinity and vacancy but smaller GLP-1 cohort), Malaysia (composite 10; reachable from Singapore bridgehead, Wegovy not yet approved as of May 2026). All three warrant later re-examination if the primary portfolio executes well, or as Singapore-launched SEA cascade markets (Malaysia in particular).
The six recommended markets fall into three temporal waves, gated by operational readiness and regulatory lead times. The sequence balances three pressures: (a) windowing — some markets have narrowing competitive windows (Australia at 12–18 months, Korea at 12–18 months); (b) regulatory lead time — some markets require ~6+ months prep (Japan FFC, UAE EDE transition, Korea MFDS); (c) operational learning compounding — each market's launch teaches operational discipline that improves the next.
Australia. TTMRA gives the lowest-friction non-NZ launch on the planet. AU is NZ's #2 export destination, premium-NZ-brand precedent is decades-deep, and the GLP-1 user base is the largest non-Anglosphere addressable cohort. Pre-launch investments lock in during NZ home launch: TGA ARTG application via TTMRA pathway, AU-resident sponsor entity, AU distribution + pharmacy retail conversations with Chemist Warehouse / Priceline, AU-native DTC infrastructure (Catch.com.au, Shopify AUD). Risk: the vacancy=2 score reflects spillover threat from Eimele, JSHealth, and Hims-owned Eucalyptus — argue for compressing the launch gap, not extending it.
South Korea. The cleanest near-term Asian launch. 400,000+ pure-private-pay GLP-1 patients already inside premium-cash supplement mindset. KGC's GLPro line is the closest competitive threat — window closes at 12–18 months. Korean local-agent partnership (Comvita/a2 Milk via Yuhan model) + MFDS HFF notified-ingredients pathway + Coupang Lemme-template launch. Target: Q3 2026 prep, Q1 2027 commercial launch.
United Arab Emirates. The Gulf beachhead. NZ-UAE CEPA in force August 2025 (98.5% duty-free entry) + Foundayo April 2026 launch creating brand-new patient cohort + EDE regulatory transition (active through 2026, stabilising mid-2026). Wait for EDE portal/document stabilisation before filing Montaji registrations; begin Halal certification (FIANZ + ESMA, 8–12 weeks) and local-agent selection in parallel. Strategic Metabolic.Health partnership conversation is the single highest-leverage move. Target: Q4 2026 / Q1 2027 soft-launch.
Singapore. SEA bridgehead. HSA framework is cleanest in Asia (no pre-market approval, English labels). Strategic value: Singapore + 650M-person SEA cascade (Malaysia, Indonesia, Thailand, Vietnam, Philippines). Pre-launch: HSA VNS dossier (start month 0, lodge 60-day notification by month 3), ACRA entity, Shopee + Lazada storefronts + standalone DTC site with PayNow/credit card. Treat as Year-1 standalone + Year-2-3 regional springboard.
Hong Kong. Premium standalone + China-mainland bridge via Tmall Global CBEC. Investments overlap with Singapore (English-first labels) and feed forward into mainland China. Sequence: Months 0–6 optimise HK standalone (Mannings/Watsons retail, SeedMedical clinic partnership); Months 6–12 open Tmall Global flagship; Months 12+ scale China presence with HK as warehousing/logistics anchor. Traditional Chinese label work de-risks both HK and Tmall Global simultaneously.
Japan. Highest-trust NZ-provenance market in Asia, with the largest documented uncontested off-label GLP-1 cohort. Heaviest regulatory + localization lift in the portfolio (FFC notification 6–14 months, Japanese-language labels mandatory, near-mandatory local fulfillment partner). Phase 1: FNFC-only multivitamin + general-food clear whey isolate, Amazon.co.jp + Rakuten Ichiba, telemedicine clinic B2B2C (Juniper Japan, Nihonbashi, elife). Phase 2 (months 18–24): FFC notification, Matsumoto Kiyoshi / Welcia drugstore pilot. Total Phase-1 budget: ~USD $100–150K.
| Wave | Market | Reg path | Reg lead time | Pre-launch budget | Strategic role |
|---|---|---|---|---|---|
| 1 | Australia | TTMRA + TGA ARTG | Weeks to ~2 months | Low — reuses NZ pack | Trans-Tasman scale |
| 2 | South Korea | MFDS HFF notified-ingredients | 3–6 months | $30–80K reg + Korean labels | Largest pure-OOP cohort |
| 2 | UAE | Dubai Municipality Montaji + Halal | 4–6 months | NZ$30–60K + ESMA Halal | Gulf beachhead |
| 3 | Singapore | HSA VNS (voluntary) | 4–8 weeks (12 with VNS) | SGD $25–50K | SEA bridgehead |
| 3 | Hong Kong | FEHD food classification | 6–10 weeks | Single-digit thousands NZD | Premium + China bridge |
| 3 | Japan | MHLW FNFC → FFC | 3–14 months | ~USD $100–150K Phase 1 | Highest-trust provenance |
The aggregate expansion-investment envelope across the six markets, including regulatory work, label localization, local agents, Halal certification, telemedicine partnership pilots, and initial channel acquisition: ~USD $400–750K spread across 18–24 months, with each wave largely self-funding from the prior wave's revenue contribution. The disciplined sequencing means no two heavy-lift markets (UAE Halal + Japan FFC) compete for the same window, and each wave's operational learnings transfer forward.
The methodology, full 41-market scorecard, per-country evidence files, and full deep-dive documents for each of the six recommended markets are preserved for audit. Each deep-dive runs ~2,000–3,000 words with 25–40 cited sources per market.
expansion-markets/pass1-methodology.mdexpansion-markets/pass1-scorecard.mdexpansion-markets/pass1-rejected.mdexpansion-markets/deep-dives/australia.mdexpansion-markets/deep-dives/uae.mdexpansion-markets/deep-dives/south-korea.mdexpansion-markets/deep-dives/japan.mdexpansion-markets/deep-dives/singapore.mdexpansion-markets/deep-dives/hong-kong.md